Morioka Masahiko
R&D, Marketing & Business Planning Division, CXS Corporation, 22 Yamashita-cho, Naka-ku, Yokohama 231-0023, Japan.
Bioorg Med Chem Lett. 2016 Dec 15;26(24):5860-5862. doi: 10.1016/j.bmcl.2016.11.020. Epub 2016 Nov 12.
A new class of a dual inhibitor of Aurora kinase and tubulin polymerization was created by introducing various substituted phenoxyethylamino or pyridyloxyethylamino groups to the 2-position of 3-cyano-4-methyl-6-(5-methyl-3-pyrazoloamino)-pyridine. Compound 3g exhibited Aurora kinase inhibition, excellent protein kinase selectivity to Aurora kinase in comparison with 66 other kinases, inhibition of phosphorylation of Ser10 of histone H3 as an Aurora kinase inhibitor, inhibition of tubulin polymerization in vitro, good cell membrane permeability, and a good PK profile. Therefore compound 3g was effective in some antitumor mouse models at a dose of 30mg/kgpoqd.
通过将各种取代的苯氧基乙氨基或吡啶氧基乙氨基基团引入到3-氰基-4-甲基-6-(5-甲基-3-吡唑啉氨基)-吡啶的2-位,合成了一类新型的Aurora激酶和微管蛋白聚合双重抑制剂。化合物3g表现出Aurora激酶抑制活性,与其他66种激酶相比,对Aurora激酶具有优异的蛋白激酶选择性,作为Aurora激酶抑制剂可抑制组蛋白H3的Ser10磷酸化,在体外抑制微管蛋白聚合,具有良好的细胞膜通透性和良好的药代动力学特征。因此,化合物3g在一些抗肿瘤小鼠模型中以30mg/kg口服每日一次的剂量有效。